-
-
Pharma & Human Health -
Pharma & Human Health -
Pharma & Human Health -
Editor's Choice
Editor’s Choice
Editor's Choice
Microbiotica Announces Impressive Results in its Phase 1b Trial of MB310 in Ulcerative Colitis
Microbiotica, a clinical-stage biopharma company developing a pipeline of oral precision microbiome medicines called live biotherapeutic products (LBPs), announces positive results in its Phase 1b First-in-Human trial, COMPOSER-1, of MB310 in ulcerative colitis (UC) patients. […]
Editor's Choice
Immunity as a Lifestyle Priority
Immune health has evolved from a seasonal concern to an essential part of everyday well-being. Consumers are adopting proactive strategies that combine healthy lifestyle habits with advanced biotic solutions, driving innovation across the supplement industry. […]
Editor's Choice
Siolta Therapeutics Reports Positive Phase 2 Results from the ADORED Study
Siolta Therapeutics, a clinical-stage biotech company developing first-in-class live biotherapeutic products (LBPs), today announced positive top-line results from the Phase 2 ADORED study (Allergic Disease Onset pREvention stuDy) of STMC-103H, its lead investigational oral microbial […]
In Case you Missed it:
Editor's Choice
Immunity as a Lifestyle Priority
Immune health has evolved from a seasonal concern to an essential part of everyday well-being. Consumers are adopting proactive strategies that combine healthy lifestyle habits with advanced biotic solutions, driving innovation across the supplement industry. […]
Pharma & Human Health
‘GABA Factory’ Probiotic LP815® Improves Sleep and Reduces Stress
Verb Biotics U.S. Consumer Health Survey of 2,000 adults reported that 73% of consumers experience symptoms related to mental health, including stress and poor sleep. Among these, 40% said their symptoms affect daily functioning, highlighting […]
Pharma & Human Health
EnteroBiotix announces positive Phase 2 results for potential first-in-class, oral, full-spectrum microbiome therapy for IBS
EnteroBiotix, a clinical-stage biopharmaceutical company focused on developing best-in-class therapies for gut health, today announced positive final results from TrIuMPH, a Phase 2a clinical trial evaluating EBX-102-02, a next-generation oral full-spectrum microbiome therapeutic, in patients […]
Pharma & Human Health
AOB Pharma receives EMA positive decision on the Pediatric Investigation Plan for development of B244
AOB Pharma, Inc. (“AOBiome”), a leading clinical-stage biotechnology company focusing on inflammatory skin conditions with their lead asset B244 for the treatment of mild to moderate atopic dermatitis (AD) and pruritus, received a positive decision […]
Pharma & Human Health
UC San Diego researchers develop new tool to predict how bacteria influence health
University of California San Diego researchers have developed an innovative new tool called coralME to better understand how microbes interact with each other and their environment to influence health. The tool rapidly creates detailed genome-scale […]
Pharma & Human Health
Traces of bacteria inside brain tumors may affect tumor behavior
Researchers at The University of Texas MD Anderson Cancer Center have uncovered unexpected traces of bacteria within brain tumors. This discovery offers new insights into the environment in which brain tumors grow and sets the […]
Pharma & Human Health
Whitepaper: Oral Drug Delivery of Live Biotherapeutics: From Development to Clinical Trial with EUDRACAP® Select
Delivering live biotherapeutics orally remains one of the challenges in microbiome therapy. In this white paper, Evonik presents a real-world case study of how EUDRACAP® Select—a ready-to-fill enteric capsule—enabled the safe and targeted delivery of […]
Editor's Choice
Siolta Therapeutics Reports Positive Phase 2 Results from the ADORED Study
Siolta Therapeutics, a clinical-stage biotech company developing first-in-class live biotherapeutic products (LBPs), today announced positive top-line results from the Phase 2 ADORED study (Allergic Disease Onset pREvention stuDy) of STMC-103H, its lead investigational oral microbial […]
